KMDA Q3 2024 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$520M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$42M+10.0% YoY

Gross Profit

$17M41.3% margin

Operating Income

$5M12.7% margin

Net Income

$4M9.3% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$20M

Stock-Based Comp.

$224,000

Balance Sheet

Total Assets

$351M

Total Liabilities

$96M

Stockholders' Equity

$255M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$38M	+10.0%
Gross Profit	$17M	$15M	+16.4%
Operating Income	$5M	$4M	+21.2%
Net Income	$4M	$3M	+19.9%